Navigation Links
NovaSperse(SM) Nanoparticle Innovator, PharmaNova, Inc., Awarded Four Government Grants Toward Development of New Therapeutic Products Under Congressional Qualifying Therapeutic Discovery Project Initiative
Date:11/8/2010

VICTOR, N.Y., Nov. 8, 2010 /PRNewswire/ -- PharmaNova, Inc., of Victor, NY, announced today that the Company has been awarded multiple grants worth in excess of $500,000 under the Qualifying Therapeutic Discovery Project (QTDP), which was created by Congress as part of the Patient Protection and Affordable Care Act of 2010. In July, PharmaNova applied for project grants to support development of multiple NovaSperse(SM)-based nanoparticulate products. NovaSperse(SM) is a unique process developed by PharmaNova for the de novo creation of nanoparticles of tightly controlled particle size. The process facilitates particle surface modifications and treatments that further influence solubility, absorption, distribution and e.g. drug-tissue targeting. Grants were awarded to PharmaNova to support further research in the areas of anti-viral treatments; new treatments for ophthalmic disease; targeted delivery of oncology medicines; and the design and development of an implantable drug delivery device. The QTDP is overseen by the Internal Revenue Service and Health & Human Services Department, and is specifically designed to assist small biotech companies engaged in competitive and innovative discoveries in healthcare.

PharmaNova will be exhibiting NovaSperse(SM) nanoparticle technology capabilities (Booth #2256) at the upcoming American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, 2010 FIP Pharmaceutical Sciences World Congress, New Orleans LA, November 14-18, 2010.

About QTDP

To be eligible, a QTDP must have the potential to develop new treatments that address "unmet medical needs" or chronic and acute diseases; reduce long-term health care costs; represent a significant advance in finding a cure for cancer; advance U.S. competitiveness in the fields of life, biological, and medical sciences; or create or sustain well-paying jobs, either directly or indirectly. Total funds available under the full Government QTDP Program are limited to $1 billion, with a per company limitation of $5 million. QTDP is only available to companies with 250 or less employees.

About PharmaNova

PharmaNova, Inc. is a privately held pharmaceutical company. Our product candidates are derived from the re-positioning and enhancement of known drugs using our proprietary NovaSperse(SM) nanoparticle technology platform. We address low-risk, fast-to-market products in areas of clear medical need and generate revenue from partnering and licensing strategies with commercialization partners and clients worldwide. PharmaNova also conducts contractual formulation development work applying NovaSperse(SM) technology to client-owned products and compounds to support new product development or the extended life cycle management of existing products. PharmaNova has new product candidates in various stages in its development pipeline. Our focus is on the development of novel, improved nanoparticle formulations of ophthalmic, anti-infective and injectable oncology products.

Members of the media, or for further information, please contact Rodney A. Brown, President, PharmaNova, Inc.: rodney.brown@pharmanovaco.com, (1) 585 413-4721.

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE PharmaNova Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
2. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
3. MicroConstants Now Offers Nanoparticle Formulation Services
4. Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate With Additional U.S. Patents
5. Researchers Use Nanoparticles as Destructive Beacons to Zap Tumors
6. Hydrox Inc., Cardinal Health Issue Nationwide Recall of Alcohol-Free Mouthwash For Hospitals
7. CMS, Inc., an Elekta Company, Announces First Cancer Patients Treated With Monaco(TM) Radiation Treatment Planning System
8. CardioVascularCS.Org, a division of EndoVascular Forum, Inc., Partners with Complex Interventional Cardiovascular Therapy (CICT) to Extend Electronic Medical Care Advancement
9. Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
10. BioStorage Technologies, Inc., Accelerates European Expansion with Opening of New German Facility
11. Nyer Medical Group, Inc., Announces Agreements to Sell Certain Eaton Apothecary Assets to Walgreens and Sell Operating Subsidiarys Stock to Investors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/19/2017)... venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound ... ... Jim Bertolina, PhD ... Tom Tefft ... device executive Josh Stopek , PhD, who has led R&D and business development teams ...
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... 12, 2017 , ... HMP , a leader in healthcare events and ... Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie ... annual award competition recognizes editorial and design excellence across a range of sectors. This ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
Breaking Medicine News(10 mins):